NCT04270669View on ClinicalTrials.gov

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Wet Age-Related Macular Degeneration
Interventions
BIOLOGICAL

intravitreal injection of RC28-E 0.5mg

The patient received one treatment of RC28-E 0.5mg in the test group

BIOLOGICAL

intravitreal injection of RC28-E 1.0mg

The patient received one treatment of RC28-E 1.0mg in the test group

BIOLOGICAL

intravitreal injection of RC28-E2.0mg

The patient received one treatment of RC28-E 2.0mg in the test group

Trial Locations (1)

100730

Beijing Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04270669 - Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter